USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY
Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
1 . A method of decreasing the risk of cardiac hospitalizations in a patient, said method comprising administering to said patient an effective amount of dronedarone or a pharmaceutically acceptable salt thereof, with food.
2 . The method according to claim 1 wherein said patient has a history of or current atrial fibrillation or flutter.
3 . The method according to claim 1 wherein the administration of dronedarone or pharmaceutically acceptable salt thereof prevents cardiovascular hospitalizations.
4 . The method according to claim 1 wherein said patient further receives a diuretic-based treatment.
5 . The method according to claim 4 wherein said diuretic is a non-potassium-sparing diuretic.
6 . The method according to claim 1 wherein the patient also exhibits at least one risk factor selected from the group consisting of:
an age greater than or equal to 75,
hypertension,
diabetes,
a history of cerebral stroke or of systemic embolism,
left atrial diameter greater than or equal to 50, and
left ventricular ejection fraction less than 40%.
7 . The method according to claim 1 wherein the dose of dronedarone administered per day, orally, is less than or equal 800 mg, measured in base form, and taken in one or more intakes.